<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82382">
  <stage>Registered</stage>
  <submitdate>29/10/2007</submitdate>
  <approvaldate>1/11/2007</approvaldate>
  <actrnumber>ACTRN12607000561482</actrnumber>
  <trial_identification>
    <studytitle>Managing Asthma in Pregnancy (MAP) Study</studytitle>
    <scientifictitle>A double-blind randomised controlled trial of FENO  guided asthma therapy and  clinical guideline guided asthma therapy in pregnant women with asthma to reduce  asthma exacerbations</scientifictitle>
    <utrn />
    <trialacronym>The MAP Study</trialacronym>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma control during pregnancy</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Asthma therapy (inhaled corticosteroid and long-acting beta-agonist therapy) adjusted according to exhaled nitric oxide measurement (FENO) during the 2nd and 3rd trimester of pregnancy (approximately 6 months)</interventions>
    <comparator>Asthma therapy (inhaled corticosteroid and long-acting beta-agonist therapy)  adjusted according to clinical guidelines (GINA) during the 2nd and 3rd trimester of pregnancy (approximately 6 months)</comparator>
    <control>Active</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Asthma exacerbations</outcome>
      <timepoint>Total number of exacerbations at end of pregnancy. Measured by monthly visits, fortnightly phonecalls and extra home or hospital visits in between these times if an exacerbation occurs</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Short-acting beta-agonist use, inhaled corticosteroid (ICS) dose, quality of life, psychological varaiables, FENO, adherence to medication, birthweight, gestational age</outcome>
      <timepoint>Short-acting beta-agonist use  &amp; ICS dose recorded monthly, quality of life and psycohological variables recorded at baseline, 1 month, 2months and 4 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>12-20 weeks gestation
Doctor diagnosis of asthma
Symptoms of asthma or taken treatment for asthma in the last 12 months</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Concomittent chronic medical illness,
chronic lung disease other than asthma, drug or alcohol dependence,
inability to attend study visits,
inability to perform spirometry,
&gt;3 courses of oral corticoseroids (OCS) in past year,
Hospital admission for an asthma exacerbation in the past 3 months,
on regular oral prednisolone or theophylline</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealed by blinded list held by independent statistician</concealment>
    <sequence>computer generated random number list stratified by ICS dose (&lt;800 mcgday or &gt;=800mcg/day) and smoking status (non/exsmokers and current smokers)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2007</anticipatedstartdate>
    <actualstartdate>28/05/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate>9/07/2010</actualenddate>
    <samplesize>210</samplesize>
    <actualsamplesize>242</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>John Hunter Hospital Royal Newcastle Centre - New Lambton</hospital>
    <hospital>The Maitland Hospital - Maitland</hospital>
    <postcode>2305</postcode>
    <postcode>2320</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Hunter New England Health</primarysponsorname>
    <primarysponsoraddress>Locked BAG # 1
 HRMC
NSW 2310</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council of Australia</fundingname>
      <fundingaddress>GPO Box 1421,
Canberrra
ACT</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Prof Peter Gibson</sponsorname>
      <sponsoraddress>Department of Respiratory &amp; Sleep Medicine
HMRI, John Hunter Hospital
Locked bag#1
HRMC 
NSW 2310</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study in pregnant women with asthma compares the guiding of asthma therapy by FENO level to asthma therapy guided by clinical guidelines on reducing asthma exacerbations during pregnancy</summary>
    <trialwebsite />
    <publication>Papers
1: Powell H, Murphy VE, Taylor DR, Hensley MJ, McCaffery K, Giles W, Clifton VL, 
Gibson PG. Management of asthma in pregnancy guided by measurement of fraction of
exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet. 2011
Sep 10;378(9795):983-90. doi: 10.1016/S0140-6736(11)60971-9. PubMed PMID:
21907861.

2: Powell H, McCaffery K, Murphy VE, Hensley MJ, Clifton VL, Giles W, Gibson PG. 
Psychosocial outcomes are related to asthma control and quality of life in
pregnant women with asthma. J Asthma. 2011 Dec;48(10):1032-40. doi:
10.3109/02770903.2011.631239. PubMed PMID: 22091740.

3: Powell H, McCaffery K, Murphy VE, Hensley MJ, Clifton VL, Giles W, Gibson PG. 
Psychosocial variables are related to future exacerbation risk and perinatal
outcomes in pregnant women with asthma. J Asthma. 2013 May;50(4):383-9. doi:
10.3109/02770903.2012.757777. Epub 2013 Jan 31. PubMed PMID: 23368420.

4: Burgess L, McCaffery K, Powell H, Murphy VE, Gibson PG, Turner RM. The
influence of asthma control on psychosocial outcomes for pregnant women with
asthma. J Asthma. 2015 Dec;52(10):1013-9. doi: 10.3109/02770903.2015.1038833.
Epub 2015 Aug 24. PubMed PMID: 26313124.

5: Powell H, Murphy VE, Hensley MJ, Giles W, Clifton VL, Gibson PG. Rhinitis in
pregnant women with asthma is associated with poorer asthma control and quality
of life. J Asthma. 2015 Dec;52(10):1023-30. doi: 10.3109/02770903.2015.1054403.
Epub 2015 Sep 12. PubMed PMID: 26365758.

Abstracts

1.	Powell H, McCaffery K, Murphy VE, Giles W, Clifton VL, Hensley MJ, McCaffery K, Gibson PG. Psychosocial outcomes are related to future exacerbation risk and perinatal outcomes in pregnant women with asthma. Respirology 2012; 17(Suppl 1):49.
2.	Powell H, Giles W, Clifton VL, Hensley MJ, Taylor DR, Murphy VE, McCaffery K, Gibson PG. Asthma exacerbations during pregnancy are reduced by inflammometry (FENO) guided asthma management: a randomised controlled trial. Am J Respir Crit Care Med 2011 3.	Steel K, McLaughlin, K, McCaffery K, Powell H, Clifton VL, Giles, W, Hensley MJ, Gibson, PG. Psychosocial characteristics and perceived medication risk in pregnant women with asthma. Respirology 2010;15(Suppl 1):A44
4.	H Powell, V Murphy, PG Gibson. The relationship between FENO and atopic status in pregnant women with asthma. Respirology 2009;14(Suppl. 1):A37.
5.	McLaughlin K, Murphy V, McCaffery K, Powell H, Clifton VL, Giles W, Hensley MJ, Gibson P. The relationship between patient perceived risk of inhaled corticosteroids in pregnancy and medication adherence. Respirology 2009;14(Suppl. 1):A42.


</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Human Research Ethics Committee</ethicname>
      <ethicaddress>Locked Bag#1
New Lambton
NSW 2305</ethicaddress>
      <ethicapprovaldate>1/03/2007</ethicapprovaldate>
      <hrec>07/02/21/3.06</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Prof Peter Gibson</name>
      <address>Department of Respiratory &amp; Sleep Medicine
HMRI, John Hunter Hospital
Locked bag#1
HRMC 
NSW 2310</address>
      <phone>0240420142</phone>
      <fax>0240420046</fax>
      <email>Peter.Gibson@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Prof Peter Gibson</name>
      <address>Department of Respiratory &amp; Sleep Medicine
HMRI, John Hunter Hospital
Locked bag#1
HRMC 
NSW 2310</address>
      <phone>0240420142</phone>
      <fax>02 498 55850</fax>
      <email>Peter.Gibson@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Heather Powell</name>
      <address>Department of Respiratory &amp; Sleep Medicine
HMRI, John Hunter Hospital
Locked bag#1
HRMC 
NSW 2310</address>
      <phone>0240420145</phone>
      <fax>0240420046</fax>
      <email>Peter.Gibson@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Peter Gibson</name>
      <address>Locked bag#1
HRMC
NSW 2310</address>
      <phone>0240420142</phone>
      <fax />
      <email>peter.gibson@hnehealth,.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>